Authors
Andreeva Y.S., Alcharki L., Shelankova A.V., Budzinskaya M.V.
Scientific Research Institute of Eye Diseases, Moscow
Abstract
Rationale: Intravitreal injections (IVI) of antivascular endothelial growth factor (anti-VEGF) have become the mainstay in the treatment of neovascular age-related macular degeneration (nAMD). Llarger number of injections and the presence of a native lens lead to a change in the parameters of the iris-lens diaphragm and are links in the violation of the hydrodynamics of the eye.
Objective: evaluate changes in the parameters of the anterior chamber after 3 IVI of the anti-VEGF drug in patients with a native lens and in patients with an intraocular lens (IOL).
Methods: The study included 34 patients with nAMD, who were divided into 2 groups: group 1 — 17 people with a native lens and group 2 — 17 people with IOL. IOP was measured with an ICare Pro before IVI (T0), 1 minute after IVI (T1), 30 minutes (T2), and 180 minutes (T3). Using a Revo NX tomograph (Optopol, Poland), the anterior chamber depth (ACD) and angle of the anterior chamber were assessed.
Results: ACD before treatment was statistically deeper in patients in group 2 (p<0.001). A statistically significant decrease in ACD was noted in group 1 before treatment and a month after three loading doses. A smaller ACD was associated with a greater rise of IOP immediately after injection in group 1 (R2 = 0.394, p<0.05). The measurements of the nasal and temporal angle before the start of treatment were statistically larger in patients with IOL (p<0.001). In group 1, there was a tendency to narrow the parameters of the nasal and temporal angle after antiangiogenic therapy (p<0.001).
Conclusion: After three IVI of anti-VEGF in patients with a native lens, there were observed statistically significant decreases in the ACD and narrowing of the nasal and temporal angle, in patients with a IOL these changes were not observed.
Keywords: anti-VEGF drugs, intravitreal injection, intraocular pressure, anterior chamber depth.
References
1. Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND,Barkmeier AJ. Trends in anti-vascular endothelial growth factor use in ophthalmology among privately insured and medicare advantage patients. Ophthalmology. 2017;124:352–358. DOI:10.1016/j.ophtha.2016.10.036
2. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355;2006:1432–1444. DOI:10.1056/NEJMoa062655
3. Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persistent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol. 2008;246:955–958. DOI:10.1007/s00417-008-0819-2
4. Wen J, Reina-Torres E, Sherwood J, Challa P, Liu K, Li G, Chang J, Cousins S, Schuman S, Mettu P, Stamer W, Overby D, Allingham R. Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration. Investigative Opthalmology & Visual Science. 2017; 58(3):1893-1898. DOI:10.1167/iovs.16-20786
5. Wingard J, Darcie A, Houlihan N, Lin J, Gieser J. Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration. Clinical Ophthalmology. 2019;13: 2563-2572. DOI:10.1016/j.ajo.2004.04.054
6. Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol.2011;89(2):138–142. DOI:10.1111/j.1755-3768.2009.016
